Physician profile
Daniel Czarnowski
NPI 1770107195
$5,711.32
in general payments reported to CMS, 2019-2025
30 companies · $1,357 in 2025
The $1,357 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $186 · 2023: $2,065 · 2024: $2,103 · 2025: $1,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,053 · Education: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,052.63 |
| Education | $472.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,615.11 | 2022-2025 | Lynparza, Imfinzi, Calquence |
| Myriad Genetic Laboratories, INC. | $738.77 | 2023-2025 | Myrisk |
| Genzyme Corporation | $493.70 | 2023-2024 | |
| Incyte Corporation | $343.97 | 2023-2025 | Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $334.93 | 2022-2025 | Ninlaro, Alunbrig, Iclusig |
| Novartis Pharmaceuticals Corporation | $278.32 | 2023-2025 | |
| Pfizer INC. | $230.57 | 2024-2025 | |
| Daiichi Sankyo INC. | $198.11 | 2024-2025 | Enhertu, Datroway |
| E.R. Squibb & Sons, L.L.C. | $180.70 | 2022-2025 | Opdivo, Opdualag |
| Tempus Ai, INC | $174.18 | 2024 | |
| Merck Sharp & Dohme LLC | $143.55 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Otsuka America Pharmaceutical, INC. | $112.84 | 2023 | Rexulti |
| Array Biopharma INC | $96.66 | 2025 | Mektovi, Braftovi, Tukysa |
| Fresenius Kabi USA, LLC | $95.60 | 2025 | Stimufend |
| Alexion Pharmaceuticals, INC. | $93.31 | 2024 | Ultomiris |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $84.79 | 2025 | |
| Amgen INC. | $81.90 | 2023-2024 | Lumakras, Evenity, Prolia |
| Celgene Corporation | $63.02 | 2023-2024 | Reblozyl, Pomalyst |
| Janssen Biotech, INC. | $57.46 | 2023-2025 | Rybrevant |
| Astellas Pharma US INC | $54.67 | 2025 | Xtandi |
| Lilly USA, LLC | $51.37 | 2023-2024 | Retevmo, Jaypirca, Verzenio |
| Geron Corporation | $31.92 | 2025 | Rytelo |
| Puma Biotechnology, INC. | $27.59 | 2023 | |
| Servier Pharmaceuticals LLC | $23.91 | 2023 | |
| Syndax Pharmaceuticals, INC. | $23.08 | 2025 | |
| Seagen INC. | $20.40 | 2023 | Tukysa |
| Adc Therapeutics America, INC. | $17.64 | 2023 | |
| Glaxosmithkline, LLC. | $17.46 | 2025 | Ojjaara |
| Intuitive Surgical, INC. | $14.78 | 2024 | |
| Pharmaand Gmbh | $11.01 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Czarnowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.